Tag: intelligence

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

New York, June 18, 2025 (GLOBE NEWSWIRE) -- According to the latest report from the World Travel & Tourism Council (WTTC), China is accelerating toward the ranks of global tourism industry "leaders" through its open approach and innovative practices. In 2025, China's domestic tourism market is projected to exceed RMB 13.7 trillion yuan, injecting robust momentum into the global economy while creating over 83 million jobs. Behind this achievement lies the multi-faceted driving force of China's policy dividends, industrial integration, and consumption upgrading, showcasing China's advantages in openness and inclusiveness, traditional culture, technological advancement, and secure environment. These strengths are attracting international visitors in droves, establishing China as the global tourism industry's "new engine."

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.